Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

New research demonstrates how specially engineered bacteria taken orally can operate as a delivery system for vaccines and antiviral therapies.